GC Green Cross Acquires Rare Blood Coagulation Disorder Pipeline from US New Drug Developer

Catalyst Biosciences Signs Asset Transfer Agreement

GC Green Cross announced on the 28th that it has signed an asset transfer agreement with the U.S. new drug development company Catalyst Biosciences regarding a pipeline related to rare blood coagulation disorders.

Heo Eun-cheol, CEO of GC Green Cross (right), and Nasim Usmankatalyst, CEO of Catalyst Biosciences (left), are taking a commemorative photo after signing an asset transfer agreement related to the rare blood coagulation disorder pipeline on the 27th.
[Photo by GC Green Cross]

Through this agreement, GC Green Cross will acquire a total of three pipelines, including 'Marzeptacog alfa (MarzAA),' which is under development in the global Phase 3 clinical stage. MarzAA has demonstrated efficacy and safety in rare blood coagulation disorders through previous clinical development. Additionally, GC Green Cross explained that since it is being developed as a subcutaneous injection formulation, it can provide dosing convenience to patients with rare blood coagulation disorders.

GC Green Cross stated that by acquiring pipelines already in clinical development stages in the U.S., it plans to continue the clinical trials aiming for new drug approval and establish a foothold for entry into the global market, including the U.S. and major advanced countries.

Since its founding, GC Green Cross has independently developed pharmaceuticals such as the plasma-derived treatment 'Greenmono' and the recombinant gene therapy 'Greenzine-F' to facilitate smooth treatment environments for hemophilia. In addition to its own drug development capabilities, the company is building and expanding its portfolio through partnerships.

Nasim Usman, CEO of Catalyst Biosciences, said, "We are pleased that this agreement with GC Green Cross will allow clinical development to continue, providing better treatments for blood coagulation disorders."

Huh Eun-cheol, CEO of GC Green Cross, said, "We will expand our efforts globally to improve the treatment environment for patients suffering from various rare diseases, including rare blood coagulation disorders."